Anebulo Pharmaceuticals Inc EBITDA Per Share 3 year CAGR is 39.32% for the quarter ending March 31, 2024. EBITDA per share represents the Earnings Before Interest, Taxes, Depreciation, and Amortization allocated to each outstanding share of common stock. It provides insight into the per-share value of EBITDA and is commonly used in valuation analysis. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.